BioSpace News Archive

Rallybio Corporation announced its participation in the following upcoming investor conferences.

BriaCell Therapeutics Corp. announces that it has accepted a letter of intent from Dr. Massimo Cristofanilli, Director of Breast Medical Oncology and Associate Director of Precision Medicine in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, outlining the parties’ plans and commitment, upon regulatory approval, to initiate a Phase 2 investigator-initiated clinical study to evaluate BriaCell’s novel immunotherapy, Bria-IMT™.

Cerevance today announced plans to present an oral presentation at the upcoming 22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium, taking place in Cambridge, United Kingdom, September 10 – 13th, 2023.

Halozyme Therapeutics, Inc. announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”) will participate in the 6th Annual Cannabinoid-Derived Drug Development Summit taking place September 11-13, 2023 in Boston, MA.

FOXO Technologies Inc. received a letter from NYSE American LLC stating that NYSE American reviewed and accepted the plan of compliance submitted by the Company in response to NYSE American’s June 12, 2023 notice informing the Company that it was not in compliance with the continued listing standards set forth in Section 1003 of the NYSE American Company Guide.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting two poster presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference.

Biocytogen Pharmaceuticals Co., Ltd. announces the official formation of two major business divisions to represent the company’s product, service, and asset portfolio.

Neurelis, Inc. will present additional clinical findings from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in people with epilepsy for ages 6 to 65 at the 35th International Epilepsy Congress (IEC) in Dublin, Ireland, September 2 to 6.

The New York Structural Biology Center and Syncell are pleased to announce a partnership to create the Optoproteomics Center of Excellence, part of the new NYSBC Proteomics Core that includes Syncell’s Microscoop platform.